Welcome to LookChem.com Sign In|Join Free
  • or
Home > Products >  > 

Sodium salicylate

Related Products

Hot Products

Name

Sodium salicylate

EINECS 200-198-0
CAS No. 54-21-7 Density 0.32 g/cm3 (20℃)
PSA 60.36000 LogP -0.24430
Solubility 1000 g/L (20 ℃) Melting Point 200 °C
Formula C7H5NaO3 Boiling Point 336.3 °C at 760 mmHg
Molecular Weight 160.105 Flash Point 144.5 °C
Transport Information N/A Appearance white crystals
Safety 26-36 Risk Codes 22-41-36/37/38
Molecular Structure Molecular Structure of 54-21-7 (Sodium salicylate) Hazard Symbols IrritantXi, HarmfulXn
Synonyms

Parbocyl-Rev;CLIN;Kerosal;Sodium 2-hydroxybenzoate;Sodium o-hydroxybenzoate;o-Hydroxybenzoic acid, sodium salt;Salsonin (TN);Enterosalil;Diuretin;Entrosalyl;Salicylic acid Na+;Aroall;Sodium salicylic acid;Salsonin;Nadisal;Magsalyl;Salisod;Benzoic acid, 2-hydroxy-, monosodium salt;Salicylic acid, sodium salt;Kerasalicyl;Alysine;Sodium salicylate (NaO3C7H5);Neo-Salicyl;Salicylic acid, monosodium salt;Benzoic acid,2-hydroxy-,compounds,monosodium salt;Sodium salicylate (JP14/USP);Monosodium salicylate;Glutosalyl;o-Hydroxybenzoic sodium salt;Salicylate, sodium;

Article Data 22

Sodium salicylate Synthetic route

124-38-9

carbon dioxide

139-02-6

sodium phenoxide

A

54-21-7

sodium salicylate

B

114-63-6

sodium 4-hydroxybenzoate

Conditions
ConditionsYield
With Triethylene glycol dimethyl ether at 80℃; for 10h; Product distribution; var. polyethers;A 80%
B 20%
at 119.84℃; under 60006 Torr; for 1h; Product distribution; Further Variations:; Pressures; N2 content; Kolbe-Schmitt reaction;
17264-78-7

sodium 2-methoxybenzoate

54-21-7

sodium salicylate

Conditions
ConditionsYield
With piperazine In N,N-dimethyl acetamide at 150℃; for 24h; Substitution; Demethylation;12%
102-09-0

bis(phenyl) carbonate

141-52-6

sodium ethanolate

A

54-21-7

sodium salicylate

B

103-73-1

Phenetole

Conditions
ConditionsYield
beim Destillieren;
3878-46-4

ethyl phenyl carbonate

139-02-6

sodium phenoxide

A

54-21-7

sodium salicylate

B

103-73-1

Phenetole

Conditions
ConditionsYield
at 200℃;

carbonic acid ethyl ester-(2-isopropyl-5-methyl-phenyl ester)

139-02-6

sodium phenoxide

A

89-83-8

thymol

B

54-21-7

sodium salicylate

C

103-73-1

Phenetole

Conditions
ConditionsYield
at 200℃;
532-32-1

sodium benzoate

A

7720-19-6

m-hydroxybenzoic acid sodium salt

B

54-21-7

sodium salicylate

C

114-63-6

sodium 4-hydroxybenzoate

Conditions
ConditionsYield
With phosphate buffer; Saline; 2-Deoxy-D-ribose; dinitrogen monoxide at 20 - 25℃; for 1h; Irradiation; var. OH scavengers;

C7H4(2)HO3(1-)*Na(1+)

54-21-7

sodium salicylate

Conditions
ConditionsYield
With water-d2 In water at 34.9℃; Equilibrium constant;
532-32-1

sodium benzoate

54-21-7

sodium salicylate

Conditions
ConditionsYield
With sulphapyridine; water Rate constant; Irradiation; also 5-, 4-, and 3-aminosalicylic acids;
69-72-7

salicylic acid

54-21-7

sodium salicylate

Conditions
ConditionsYield
With KU-2(Na) Equilibrium constant; exchange equilibrium constant;
With sodium hydroxide In ethanol at 20℃;
102-09-0

bis(phenyl) carbonate

sodium hydroxide

sodium hydroxide

A

54-21-7

sodium salicylate

B

108-95-2

phenol

Conditions
ConditionsYield
beim Destillieren;

Sodium salicylate Consensus Reports

Reported in EPA TSCA Inventory.

Sodium salicylate Specification

The Sodium salicylate, with the CAS registry number 54-21-7, is a kind of white powder. This is easily soluble in water(1:0.8,25℃) and glycerol while insoluble in ether, chloroform and  benzene. Being stable chemically while incompatible with mineral acids and metallic salts, this chemical is light-sensitive.

The physical properties of Sodium salicylate are as follows: (1)ACD/LogP: 2.06; (2)# of Rule of 5 Violations: 0; (3)ACD/LogD (pH 5.5): -0.93; (4)ACD/LogD (pH 7.4): -1.09; (5)ACD/BCF (pH 5.5): 1; (6)ACD/BCF (pH 7.4): 1; (7)ACD/KOC (pH 5.5): 1; (8)ACD/KOC (pH 7.4): 1; (9)#H bond acceptors: 3; (10)#H bond donors: 2; (11)#Freely Rotating Bonds: 2; (12)Polar Surface Area: 46.53; (13)Flash Point: 144.5 °C; (14)Enthalpy of Vaporization: 61.16 kJ/mol; (15)Boiling Point: 336.3 °C at 760 mmHg; (16)Vapour Pressure: 4.45E-05 mmHg at 25°C; (17)Exact Mass: 160.013639; (18)MonoIsotopic Mass: 160.013639; (19)Topological Polar Surface Area: 60.4; (20)Heavy Atom Count: 11; (21)Complexity: 138.

The production method of Sodium salicylate: Add salicylic acid and sodium bicarbonate into the distilled water with the temperature of 60℃, and then add EDTA and sodium hydrosulfite with defined amount; Next heat it to 85℃ and react for about half an hour; Lastly filter the qualified reaction liquid into the fluidized bed and then dry to 85℃ to get this product.

As to its usage, it is widely applied in many ways. It could be used in organic synthetic materials, antiseptic, the reagent testing the gastric acid in the free agents; It could also be used as the drug with the function of being antifebrile and anti-rheumatic. In addition, it is also a potential replacement for aspirin for people sensitive to it.

When you are dealing with Sodium salicylate , you should be much more cautious. For one thing, it is irritant to eyes, respiratory system and skin, which may also cause inflammation to the skin or other mucous membranes. For another thing, it is harmful which may cause damage to health and it may have risk of serious damage to eyes. Therefore, you should wear suitable protective clothing. If in case of contact with eyes, rinse immediately with plenty of water and seek medical advice.

In addition, you could convert the following datas into the molecular structure:
(1)Canonical SMILES: C1=CC=C(C(=C1)C(=O)[O-])O.[Na+]
(2)InChI: InChI=1S/C7H6O3.Na/c8-6-4-2-1-3-5(6)7(9)10;/h1-4,8H,(H,9,10);/q;+1/p-1
(3)InChIKey: ABBQHOQBGMUPJH-UHFFFAOYSA-M 

Below are the toxicity information of Sodium salicylate:

Organism Test Type Route Reported Dose (Normalized Dose) Effect Source
child TDLo multiple routes 2970mg/kg/13D (2970mg/kg) BEHAVIORAL: EXCITEMENT

GASTROINTESTINAL: NAUSEA OR VOMITING
American Journal of Diseases of Children. Vol. 69, Pg. 37, 1945.
dog LD50 intravenous 562mg/kg (562mg/kg) BEHAVIORAL: ANALGESIA Archives Internationales de Pharmacodynamie et de Therapie. Vol. 149, Pg. 571, 1964.
 
dog LDLo intraperitoneal 990mg/kg (990mg/kg)   "Abdernalden's Handbuch der Biologischen Arbeitsmethoden." Vol. 4, Pg. 1392, 1935.
dog LDLo oral 450mg/kg (450mg/kg)   "Abdernalden's Handbuch der Biologischen Arbeitsmethoden." Vol. 4, Pg. 1392, 1935.
dog LDLo subcutaneous 200mg/kg (200mg/kg) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD

LUNGS, THORAX, OR RESPIRATION: DYSPNEA

LUNGS, THORAX, OR RESPIRATION: OTHER CHANGES
Revue Medicale de la Suisse Romande. Vol. 15, Pg. 561, 1895.
frog LDLo subcutaneous 250mg/kg (250mg/kg)   "Abdernalden's Handbuch der Biologischen Arbeitsmethoden." Vol. 4, Pg. 1392, 1935.
guinea pig LDLo intraperitoneal 900mg/kg (900mg/kg)   "Abdernalden's Handbuch der Biologischen Arbeitsmethoden." Vol. 4, Pg. 1392, 1935.
guinea pig LDLo subcutaneous 800mg/kg (800mg/kg) CARDIAC: ARRHYTHMIAS (INCLUDING CHANGES IN CONDUCTION)

BEHAVIORAL: EXCITEMENT

LUNGS, THORAX, OR RESPIRATION: DYSPNEA
Revue Medicale de la Suisse Romande. Vol. 15, Pg. 561, 1895.
human LDLo oral 700mg/kg (700mg/kg) BEHAVIORAL: EXCITEMENT

BEHAVIORAL: MUSCLE CONTRACTION OR SPASTICITY)

LUNGS, THORAX, OR RESPIRATION: DYSPNEA
New England Journal of Medicine. Vol. 232, Pg. 617, 1945.
mouse LD50 intramuscular 760mg/kg (760mg/kg)   Acta Paediatrica Scandinavica. Vol. 59, Pg. 517, 1970.
 
mouse LD50 intraperitoneal 500mg/kg (500mg/kg)   Strahlentherapie. Vol. 127, Pg. 245, 1965.
 
mouse LD50 intravenous 500mg/kg (500mg/kg)   British Patent Document. Vol. #1009195,
mouse LD50 oral 540mg/kg (540mg/kg)   Arzneimittel-Forschung. Drug Research. Vol. 5, Pg. 572, 1955.
 
mouse LD50 subcutaneous 550mg/kg (550mg/kg)   Arzneimittel-Forschung. Drug Research. Vol. 8, Pg. 25, 1958.
 
rabbit LD50 intravenous 415mg/kg (415mg/kg)   Kiso to Rinsho. Clinical Report. Vol. 13, Pg. 791, 1979.
rabbit LD50 oral 1700mg/kg (1700mg/kg)   Journal of Pharmacology and Experimental Therapeutics. Vol. 89, Pg. 205, 1947.
rat LD50 intraperitoneal 542mg/kg (542mg/kg)   Kiso to Rinsho. Clinical Report. Vol. 13, Pg. 791, 1979.
rat LD50 oral 930mg/kg (930mg/kg) BEHAVIORAL: CONVULSIONS OR EFFECT ON SEIZURE THRESHOLD

BEHAVIORAL: MUSCLE CONTRACTION OR SPASTICITY)
Science Reports of the Research Institutes, Tohoku University, Series C: Medicine. Vol. 36(1-4), Pg. 10, 1989.
women TDLo unreported 1400mg/kg (1400mg/kg) BEHAVIORAL: TOXIC PSYCHOSIS

LUNGS, THORAX, OR RESPIRATION: RESPIRATORY STIMULATION

SKIN AND APPENDAGES (SKIN): SWEATING: OTHER
JAMA, Journal of the American Medical Association. Vol. 126, Pg. 806, 1944.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 54-21-7